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Original Article
Retinopathy of prematurity (ROP) is a proliferative retinal 
vascular disease exclusive to premature infants, and a major 
cause of childhood blindness [1,2]. Blood vessel growth in 
immature retinas of premature infants is disrupted due to 
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Purpose: To investigate the efficacy, safety, and anatomical outcomes associated with intravitreal anti-vascular 
endothelial growth factor (VEGF) treatment of retinopathy of prematurity (ROP).
Methods: We performed a retrospective review of intravitreal anti-VEGF (bevacizumab or ranibizumab) treat-
ment of 153 eyes (83 infants) diagnosed with ROP at two tertiary hospitals from June 2011 to January 2017. 
The primary outcome was the rate of recurrence requiring additional treatment; secondary outcomes included 
incidence of major complications and final refractive error.
Results: A total of 101 eyes were treated with bevacizumab, and 52 with ranibizumab. The bevacizumab and ra-
nibizumab groups were characterized by mean birthweights of 941.8 ± 296.1 and 1,257.7 ± 514.5 g, gestational 
ages at birth of 26.9 ± 1.9 and 28.1 ± 3.2 weeks, and postmenstrual ages at treatment of 40.4 ± 2.4 and 39.2 
± 2.3 weeks, respectively. The two groups differed significantly in birthweights and gestational ages at birth, 
but not in postmenstrual ages at treatment. The mean follow-up duration was 30.9 ± 18.4 months for the bev-
acizumab group, and 13.9 ± 12.5 months for ranibizumab. More cases were classified as zone 1 ROP in the 
ranibizumab group (44.2% vs. 11.9%, p < 0.001). Major surgical interventions included scleral encircling and 
vitrectomy (one and two eyes, respectively, both in the bevacizumab group). Retinal detachment was noted 
in one eye treated with bevacizumab. There was no significant difference in the most recent spherical equiv-
alence for the two groups (+0.10 ± 3.66 and +0.22 ± 3.00 diopters for bevacizumab and ranibizumab, respec-
tively). Univariable analysis revealed that only ROP stage influenced the occurrence of major complications 
(odds ratio, 9.046; p = 0.012).
Conclusions: Intravitreal anti-VEGF treatment of ROP with both bevacizumab and ranibizumab achieved stable 
retinal vascularization with a low rate of complications and recurrence. Ranibizumab achieved similar anatomi-
cal outcomes as bevacizumab, without additional risk for major complications.
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lung immaturity and respiratory distress syndrome [2,3]. 
Exposure to relative hyperoxia and subsequent hypoxia in-
duces release of vascular endothelial growth factor 
(VEGF), causing abnormal blood vessel growth in the reti-
na, leading to retinal detachment and severe visual disabili-
ties [4,5]. ROP contributes to 3% to 10% of childhood 
blindness worldwide [6-9]. A survey of the Korean Neona-
tal Network database found that the total incidence rate of 
ROP was 34.1% among very-low-birth-weight infants, with 
33.7% of these infants requiring treatment [10]. 
Following landmark studies such as the 2011 Bevacizum-
ab Eliminates the Angiogenic Threat (BEAT)-ROP study 
[11], there has been widespread use of anti-VEGF injections 
as the primary treatment for zone 1 and posterior zone 2 
ROP. The benefits of intravitreal anti-VEGF therapy in-
clude increased peripheral vascularization with resulting 
improvement in the visual field, less macular dragging, less 
pathological myopia, and the ease of the procedure without 
need for general anesthesia [12]. However, several studies 
have shown systemic suppression of VEGF and other 
growth factors after intravitreal anti-VEGF injection in 
neonatal infants [13,14], raising concerns about neurological 
or developmental delay [15]. There have also been isolated 
reports of retinal detachment [16-18] and endophthalmitis 
[19] following intravitreal injections.
Bevacizumab has been more widely reported than ran-
ibizumab for treating ROP [11,20], but the use of ranibi-
zumab has increased recently due to its theoretically safer 
systemic profile [21,22]. Bevacizumab is a humanized 
monoclonal murine antibody that binds all VEGF isoforms; 
ranibizumab is a humanized recombinant antibody frag-
ment derived from bevacizumab, with approximately ten-
fold greater binding affinity [23]. Due to the smaller molec-
ular weight of ranibizumab (48 vs. 149 kDa) and its shorter 
intravitreal half-life (26% that of bevacizumab) [24], ran-
ibizumab is expected to clear faster from systemic circula-
tion, potentially reducing systemic exposure and the risk of 
neurologic developmental defects [25].
In this study we compared the efficacy, anatomical out-
comes, and rates of complications of anti-VEGF therapy 
for ROP using bevacizumab and ranibizumab.
Materials and Methods  
Study design
 This was a retrospective study conducted in two tertiary 
referral-based hospitals, Severance Hospital and Gangnam 
Severance Hospital, affiliated with Yonsei University Col-
lege of Medicine. Patients diagnosed with ROP who received 
intravitreal anti-VEGF treatment from June 2011 to January 
2017 were included, and their medical records were re-
viewed. All infants with ROP who required treatment were 
hospitalized in neonatal intensive care units. This study was 
conducted with the approval of our institutional review 
board (3-2018-0050) and adhered to the principles of the 
Declaration of Helsinki. The legal guardian of each patient 
signed a consent form before any examination or treatment.
Screening and treatment
 Infants were screened for ROP if their gestational age at 
birth (GA) was <32 weeks and their birth weight (BW) was 
<1,500 g, or if they had an unstable clinical course as deter-
mined by the primary neonatologist. All examinations 
were performed by qualified ophthalmologists using the 
2005 International Classification of Retinopathy of Prema-
turity [26]. Indications for treatment were infants who met 
criteria for type 1 ROP as defined in the ETROP (Early 
Treatment for Retinopathy of Prematurity) study [27], al-
though earlier treatment was performed in some cases at 
the discretion of the primary ophthalmologist.
Intravitreal anti-VEGF—either bevacizumab (0.625 
mg/0.025 mL; Avastin, Genentech, San Francisco, CA, 
USA) or ranibizumab (0.2 mg/0.02 mL; Lucentis, Novartis, 
Basel, Switzerland) [28,29]—was injected into each eye, 
with a gradual change in preference over the study period 
from bevacizumab to ranibizumab due to reports of safer 
systemic profiles for ranibizumab. The following tech-
niques were used: topical anesthesia, sterile gloves, lid mar-
gin cleaned with povidone-iodine swabs, patient’s face cov-
ered with a surgical towel with eye holes, insertion of a lid 
speculum, instillation of topical povidone-iodine, indenta-
tion of 0.5 to 1 mm posterior to the limbus with surgical 
calipers, injection of anti-VEGF with a sterile 30-gauge 
needle, removal of the needle with simultaneous compres-
sion using a sterile cotton tip, instillation of topical tobra-
mycin, and removal of the speculum. New equipment was 
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used for the fellow eye. Patients were reexamined the sub-
sequent day and then weekly to monitor disease progres-
sion. Additional treatments such as additional injections, 
laser treatment, or surgeries such as vitrectomy and scleral 
encircling were performed as needed.
Patients were divided into bevacizumab and ranibizum-
ab groups. The primary outcomes were ROP recurrences 
requiring retreatment, refractive errors, and major compli-
cations, defined as corneal opacity requiring transplanta-
tion, lens opacity requiring cataract surgery, retinal or 
vitreous hemorrhage requiring vitrectomy, retinal detach-
ment, optic atrophy and glaucoma surgery, as well as major 
systemic complications such as death.
Data analysis
Statistical analysis was performed using IBM SPSS Sta-
tistics ver. 22.0 (IBM Corp., Armonk, NY, USA). Kol-
mogorov-Smirnov tests were used to analyze sample distri-
butions. The independent t-test, the Mann-Whitney rank-
sum test, the chi-square test, and the Fisher exact test were 
used. Logistic regression analyses were performed to assess 
the impact of patient and treatment factors on outcomes. A 
p-value <0.05 was considered statistically significant.
Results
A total of 153 eyes from 83 infants were included in the 
study: 101 eyes treated with bevacizumab, and 52 with ra-
nibizumab. The sex ratio, mean BW, GA, ROP classifica-
tion, follow-up duration, and other baseline characteristics 
are shown in Table 1. The mean GA was 27.3 weeks over-
all, with a significant difference between the two groups 
(26.9 for bevacizumab, 28.1 for ranibizumab; p = 0.013). 
Accordingly, mean BW was higher in the ranibizumab 
Table 1. Summary of ROP patients treated with intravitreal anti-vascular endothelial growth factor
Overall Bevacizumab Ranibizumab p-value*
Primary initial treatment 153 (100) 101 (66.0) 52 (34.0)
Sex
Male 83 (54.2) 62 (61.4) 21 (40.4) 0.017†
Female 70 (45.8) 39 (38.6) 31 (59.6) 0.017†
Birthweight (g) 1,049.2 ± 411.1 941.8 ± 296.1 1,257.7 ± 514.5 <0.001†
GA at birth (wk) 27.3 ± 2.5 26.9 ± 1.9 28.1 ± 3.2 0.013†
PMA at initial treatment (wk) 40.0 ± 2.3 40.4 ± 2.4 39.2 ± 2.3 0.090
Initial ROP classification    
Stage
2 16 (10.5) 6 (5.9) 10 (19.2) 0.022†
3 137 (89.5) 95 (94.1) 42 (80.8) 0.022†
Zone
1 34 (22.2) 13 (12.9) 21 (40.4) <0.001†
2 107 (69.9) 78 (77.2) 29 (55.8) 0.009†
3 12 (7.8) 10 (9.9) 2 (3.8) 0.223
Presence of plus sign 88 (57.5) 66 (65.3) 29 (55.8) 0.292
Presence of pre-plus sign 57 (37.3) 37 (36.6) 20 (38.5) 0.861
APROP 11 (7.2) 5 (5.0) 6 (11.5) 0.186
Tunica vasculosis lentis 24 (15.7) 12 (11.9) 12 (23.1) 0.099
Total follow-up duration (mon) 25.1 ± 1.5 30.9 ± 18.4 13.9 ± 12.5 <0.001†
Values are presented as number (%) or mean ± standard deviation. 
ROP = retinopathy of prematurity; GA = gestational age; PMA = post-menstrual age; APROP = aggressive posterior retinopathy of 
prematurity.
*Bevacizumab vs. ranibizumab; †p < 0.05.
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group (1,257.7 vs. 941.8 g, p < 0.001). There was no differ-
ence in mean postmenstrual age at primary treatment, 
which was 40.0 weeks overall. There was no difference in 
the proportion of eyes classified as type 1 ROP (62.4% for 
bevacizumab, 55.8% for ranibizumab; p = 0.487) or in ag-
gressive posterior ROP (5.0% for bevacizumab, 11.5% for 
ranibizumab; p = 0.186). There were more eyes with zone 1 
ROP in the ranibizumab group (40.4% vs. 12.9%, p < 0.001). 
There was a significantly longer mean follow-up period for 
the bevacizumab group (30.9 vs. 13.9 months, p < 0.001). 
ROP recurrences requiring additional treatment are sum-
marized in Table 2. A total of 15 (9.8%) eyes had recur-
rences that required further intervention. Major interven-
tions such as scleral encircling (one eye) or vitrectomy (two 
eyes) were required in a few cases in the bevacizumab 
group. Further treatment with laser photocoagulation was 
needed in one case following bevacizumab treatment. 
More eyes required additional anti-VEGF therapy follow-
ing treatment with ranibizumab than bevacizumab (13.5% 
vs. 4.0%, p = 0.037).
Major complications and anatomical outcomes are shown 
in Table 3. Retinal detachment and temporal macular drag-
ging each occurred in one eye in the bevacizumab group. 
Spherical equivalence at the most recent visit was +0.11 ± 
3.58 diopters (D) overall, with no significant difference be-
tween the two groups (p = 0.922). There were more eyes 
with retinas fully vascularized to the ora serrata at follow-
up in the bevacizumab group than in the ranibizumab group 
(100% vs. 85.0%, p < 0.001). The mean age at the most re-
cent follow-up was 2.3 years old overall, and was higher in 
Table 2. Retinopathy of prematurity recurrence requiring additional treatment after intravitreal anti-VEGF
Overall
(n = 153)
Bevacizumab 
(n = 101)
Ranibizumab 
(n = 52) p-value
*
Additional laser 1 (0.7) 1 (1.0) 0 (0) 0.660
Additional anti-VEGF injection  11 (7.2) 4 (4.0) 7 (13.5) 0.037†
Scleral encircling/buckling 1 (0.7) 1 (1.0) 0 (0) 0.660
Vitrectomy 2 (1.3) 2 (2.0) 0 (0) 0.548
VEGF = vascular endothelial growth factor.
*Bevacizumab vs. ranibizumab; †p < 0.05.
Values are presented as number (%) or mean ± standard deviation.
*Bevacizumab vs. ranibizumab; †p < 0.05.
Overall 
(n = 153)
Bevacizumab 
(n = 101)
Ranibizumab 
(n = 52) p-value
*
Complications
Retinal detachment 1 (0.7) 1 (1.0) 0 (0) 0.660
Vitreous hemorrhage 2 (1.4) 1 (1.0) 1 (1.9) 0.566
Macular dragging 1 (0.7) 0 (0) 1 (1.9) 0.340
Cataract 1 (0.7) 1 (1.0) 0 (0) 0.660
Pale disc without known neurologic defects 8 (1.4) 4 (4.0) 4 (7.7) 0.445
Glaucoma 0 (0) 0 (0) 0 (0) -
Known systemic complications (e.g., death) 0 (0) 0 (0) 0 (0) -
Strabismus operation 21 (13.7) 21 (20.8) 0 (0) <0.001†
Vascularization to ora serrata 130 (95.6) 96 (100) 34 (85.0) <0.001†
Age at most recent follow-up (yr) 2.3 ± 1.5 2.8 ± 1.5 1.3 ± 1.0 <0.001†
Final spherical equivalence (diopter) +0.11 ± 3.58 +0.10 ± 3.66 +0.22 ± 3.00 0.922
Table 3. Major complications and anatomical outcomes after anti-vascular endothelial growth factor injection for retinopathy of 
prematurity
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the bevacizumab group (2.8 vs 1.3 years, p < 0.001).
Univariable analysis of patient and treatment factors in-
f luencing the incidence of major complications revealed 
that only ROP stage was a significant factor (Table 4), with 
ROP stage 3 having a much higher odds ratio than ROP 
stage 2 (odds ratio, 9.046; p = 0.012). No patient or treat-
ment factors were associated with retinal detachment (data 
not shown).
Discussion
Anti-VEGF injections promote retinal vascularization 
without permanent destruction of the peripheral retina, and 
are less time-consuming or risky than conventional laser 
therapy. However, many ophthalmologists still question the 
use of anti-VEGF as the primary treatment for ROP, due to 
concerns regarding long-term complications. From January 
2013 to June 2014 in Korea, of 231 very-low-birth-weight 
infant eyes treated for ROP, 63.6% received only an opera-
tion (laser, cryotherapy, or surgery), 16.9% received only 
anti-VEGF treatment, and 19.5% received both an opera-
tion and an anti-VEGF injection [10]. We investigated the 
efficacy, anatomical outcomes, and complications associat-
ed with intravitreal anti-VEGF ROP treatment using beva-
cizumab and ranibizumab.
In our study, 22% of cases of zone 1 ROP and 40% of 
“pre-plus” retinas were treated with anti-VEGF. These 
high anti-VEGF treatment rates may be due to a recent 
change in our centers to aggressively treating ROP with 
anti-VEGF at earlier time points. ROP is a biphasic dis-
ease, with a vaso-obliterative phase in which VEGF secre-
tion is stimulated by relative hypoxia in the peripheral 
avascular retina, followed by a vasoproliferative phase 
[30,31]. A single burst of VEGF promotes vascular growth 
in ROP [32], which is different from other ocular neovas-
cular diseases such as exudative neovascular age-related 
macular degeneration, in which there is continual VEGF 
release. Delayed anti-VEGF treatment, administered when 
VEGF levels are decreasing, may not be as effective and 
may promote fibrosis [33,34]. Accordingly, in our study the 
overall rate of ROP recurrence requiring additional treat-
ment was 9.8%, lower than in previous studies (13% to 
35.4%) [20,22,28].
Significantly more eyes required additional anti-VEGF 
treatment in the ranibizumab group. This may be because 
ranibizumab has a shorter intravitreal half-life than bevaci-
zumab due to its smaller molecular weight [24]. The ranibi-
zumab group also had a greater proportion of zone 1 ROP, 
which requires more time for full vascularization following 
initial anti-VEGF treatment. During the extended period of 
vascular growth, elevation in VEGF levels may reactivate 
ROP, requiring additional anti-VEGF treatment [35]. 
In terms of safety, anti-VEGF injections appear to cause 
few cases of retinal detachment or macular temporal drag-
ging, as only one case of each occurred (both in the beva-
cizumab group). Furthermore, there was no significant dif-
ference in incidence of major complications following 
ranibizumab and bevacizumab treatments (odds ratio, 
8.275; p = 0.501). Though both anti-VEGF agents enter sys-
temic circulation following intravitreal injection [36,37], 
ranibizumab appears to suppress systemic VEGF for less 
time than bevacizumab, and to clear more rapidly from 
systemic circulation [36,38]. Therefore, ranibizumab is the-
oretically safer in its systemic profile, with less risk of neu-
rologic deficits or developmental delays. In our analysis, 
more injections were required in the ranibizumab group, 
Table 4. Univariable analysis of factors inf luencing occur-
rence of major complications (retinal detachment, optic atro-
phy, cataract surgery) after anti-VEGF injection for ROP
OR (95% CI) p-value
Anti-VEGF agent
Bevacizumab 1 (reference)
Ranibizumab 8.275 (0.018–3881) 0.501
Sex
Male 1 (reference)
Female 0.130 (0.015–1.108) 0.062
Birthweight (g) 0.995 (0.987–1.003) 0.229
GA at birth 3.498 (0.223–54.769) 0.372
PMA age at initial treatment 0.124 (0.005–2.901) 0.195
Initial ROP classification
Stage
2 1 (reference)
3 9.046 (1.635–50.061) 0.012*
Presence of pre-plus sign 0.323 (0.024–4.272) 0.391
Tunica vasculosis lentis 1.549 (0.004–613.492) 0.886
VEGF = vascular endothelial growth factor; ROP = retinopathy 
of prematurity; OR = odds ratio; CI = confidence interval; GA = 
gestational age; PMA = post-menstrual age.
*p < 0.05.
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but there were cases in the bevacizumab group which re-
quired major interventions such as scleral encircling/buck-
ling or vitrectomy (the number of cases was too small for 
statistical comparison). There were no major systemic com-
plications in either group.
Full retinal vascularization to the ora serrata by the most 
recent follow-up was achieved in more cases in the bevaci-
zumab group than in ranibizumab group (100% vs. 85.0%, 
p < 0.001). This may be due to the shorter follow-up period 
for the ranibizumab group (the mean age at the most recent 
follow-up was 2.3 years for bevacizumab, 1.3 years for ra-
nibizumab; p < 0.001). There have been conflicting reports 
regarding the rate of retinal abnormalities and incomplete 
vascularization in long-term follow-up of ROP infants re-
ceiving anti-VEGF. For example, Castellanos et al. [39] fol-
lowed six eyes of ROP patients receiving ranibizumab for 
three years and found fully vascularized retinas with no 
fluorescein leakage on angiography in all eyes. Isaac et al. 
[40] found peripheral vascularization to the ora serrata in 
four of five eyes that received bevacizumab, with one pa-
tient having too short a follow-up to determine vasculariza-
tion potential properly. Huang et al. [22] noted incomplete 
vascularization without reactivation after ranibizumab 
treatment in 2.8% of 286 eyes. The BEAT-ROP study 
found the full vascularization rate to be 95.7% in 140 eyes. 
However, there have also been less favorable reports. Wu et 
al. [20] reported full vascularization in 88.0% of 162 beva-
cizumab-treated eyes, and Chen et al. [28] reported full 
vascularization in only 46.4% of 151 ranibizumab-treated 
eyes. In our study, we noted a full vascularization rate of 
95.6% of 136 eyes receiving anti-VEGF treatment, with the 
remaining eyes having too short a follow-up period to 
properly determine the vascularization potential.
Refractive error at the most recent follow-up revealed as-
sociation with mild hyperopia, with similar values for ra-
nibizumab and bevacizumab. These results are consistent 
with previous results, which showed less association with 
myopia in anti-VEGF–treated eyes [12,41].
This study has several limitations. First, it was a retro-
spective study with a variable follow-up period and without 
appropriate controls; as such, significant differences in a 
few baseline characteristics between the treatment groups 
were noted. Second, the study population was limited to 
Asian patients in a tertiary hospital setting. Third, systemic 
complications may not have been properly observed or re-
ported by the neonatologists. Last, we did not routinely 
perform fluorescein angiography to document fully vascu-
larized retinas; however, the primary retina specialist per-
formed thorough fundus examinations at each follow-up 
visit. The strengths of this study include the large number 
of patients with a mean follow-up period >12 months, and 
all patients being treated at only two hospitals using the 
same treatment protocols.
In conclusion, we found that intravitreal anti-VEGF in-
jections achieve stable retinal vascularization with a low 
rate of complications and recurrences requiring additional 
treatment. Ranibizumab appears to achieve similar ana-
tomical outcomes as bevacizumab, without additional risk 
for major complications such as retinal detachment or sys-
temic side effects.
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